Efficacy and safety of RP1 plus nivolumab in patients with non-melanoma skin cancer

EJC Skin Cancer 2026 Open access

Read full text
Authors: D. Schadendorf, M.K. Wong, G.M. Beasley, A.C. Pavlick, K.J. Harrington, B. Chmielowski, J. Niu, A.M. VanderWalde, T.L. Bowles, K.K. Tsai, E.T. Hall, T.M. Wise-Draper
+7 more J. Michels, A. Arance, M. Amini-Adle, J. Zhu, M. Viana, J.W. Hou, M.M. Milhem
DOI: 10.1016/j.ejcskn.2026.100982
Cited by: 1

Abstract

Background: Patients with non-melanoma skin cancer (NMSC) that has progressed on an anti–PD-(L)1–containing therapy have poor clinical outcomes and limited treatment options. RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy that expresses human granulocyte-macrophage colony-stimulating factor and a fusogenic glycoprotein (GALV-GP-R−). Here, we report the efficacy of RP1 + nivolumab from the NMSC cohort of the phase 1/2 IGNYTE trial (NCT03767348).

Fields of Study & Subjects

Nonmelanoma Skin Cancer Studies Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways

Publication details

Journal / source
EJC Skin Cancer
Publisher
Elsevier BV
Volume
4
Pages
100982–100982
Publication date
1 January 2026
Language
EN